

## CV values from historical trials as a quality measure: a tool

CV-Werte von historischen Versuchen als Qualitätsmesslatte für Bewertungen: ein Werkzeug

#### ////////

Sommertagung AG Landwirtschaftliches Versuchswesen 27-28 June 2019, IPK Gatersleben

Peter Lancashire and Yinfei Li Bayer AG Crop Science Field Solutions Monheim, Germany





#### Agenda

- // Bayer field trials
- // EPPO standards
- // Coefficient of variation
- // Scout field trials system
- // Examples of reference distributions
- // CV inspector tool
- // Discussion and questions





Bayer conducts around 20000 crop protection field trials globally each year.

They are used to investigate, develop, register and support new product solutions for farmers and growers.

Tea plots in Japan



**Bayer field trials** 



Sugar beet damaged by pests





Potato infected with late blight



## European and Mediterranean Plant Protection Organization (EPPO) Standards



The EPPO Standards for the efficacy evaluation of plant protection products (PP1) describe the **conduct of trials** carried out to assess the **efficacy** of plant protection products against specific pests.

They are addressed to all institutions, official registration authorities, public institutes or **private firms** carrying out such trials.

In Europe, they now constitute a reference in Commission Regulation (EU) No 545/2011 of 10 June 2011, implementing Regulation (EC) No 1107/2009 of the European Parliament and of the Council regarding the **data requirements** for plant protection products.

#### PP 1/152(4) Design and analysis of efficacy evaluation trials

- // Relevant standard for statistics
- // Implemented by Bayer

Efficacy evaluation of plant protection products Evaluation biologique des produits phytosanitaires Design and analysis of efficacy eva	luation trials
Specific scope This standard is intended for use in association with EPPO Standards of set PF 1 Standards for the efficacy evaluation of plant protection products and provides detailed advice on the design and analysis of efficacy evaluation trials.	Specific approval and amendmynt First approval in 1989-09. First trysision approved in 1998-09. Second revision approved in 2006-09. Revision mainly to reflect zonal assessment approved in 2012-09.
Introduction	1. Experimental design
This standard is intended to provide general background information on the design and analysis of effects; evaluation of platt protection products provide more detailed instruc- tions on nucl trails for individual horigest combinations. The streps of a visit is frust considered (reperimental design of the stress of the stress of the stress of the weight of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of the stress of stress stress of stress stress of stress attempt to reveal the principles of sould statical precision attempt to reveal the principles of statistical precision stress of stress of the block of the stress of statistical precision is not been the provide a stress of statistical recipes to be followed bindy.	<text><text><text><text></text></text></text></text>
© 2012 OEPP/EPPO, Bulletin OEPP/EPPO Bulletin 42, 367-381	AND



### EPPO Guideline PP 1/152(4) Design and analysis of efficacy evaluation trials

3.4.4 Basic structure and sequence of analysis

Before beginning statistical analysis of the results of a trial series, the data of each trial should be validated.

- // Methodological validation ...
- // Agronomic and biological validation ...
- // Statistical validation: trials should be accurate, showing a typical standard error (or coefficient of variation).

#### **Questions**

- // What is a coefficient of variation?
- // What values are typical?
- // How can we validate trial data in practice?

_		
0 EPI	*O - Licenced for BCS - Bayer CropScience AG (#0280-077)	Design and analysis of efficacy evaluation trials 379
	3.4.1 Definition For the purposes of this standard, a trial series can be defined as a set of treatments tested under different environ- mental conditions in one or several years. The set of treat- ments belonging to a series should be aroundwate toreaber.	showing a level of interaction that is unacceptably large should be analyzed and discussed separately. 3.45 <i>Choice of statistical method</i> 4.5 for an individual trial method
	using the same statistical model.	mined by the type of variable to be analysed. The methods to be used are the same or similar to those used for an indi-
	3.4.2 Planning When planning a trial series experimenters should consider defining the trial question and all relevant parameters, i.e. core treatment list, trial design and replicates, number of sites, test methods, etc., that are required to apply the bio- metrical model planned to be used for the trials series anal-	vidual trial (e.g. analysis of variance, non-parametric meth- ods). The main purpose of the analysis of a trial series is to measure and test the interactions between the test products and the environment or site, i.e. showing that the differ- ences between products are 'equal' on every site. The trials can be grouped in advance of the analysis, according to
	ysis. 3.4.3 Goals	appropriate criteria (e.g. soil type, level of infestation), or afterwards, using the analytical methods and results of the interactions to group the trials accordingly.
	The objectives of analysis are: • To estimate treatment effects over sites and years; • To test the interactions between treatments, sites and	Acknowledgements
	<ul> <li>years. Environmental and other differences between sites and years may confound these factors;</li> <li>Possibly also to test the significance of differences between treatments and standards.</li> </ul>	EPPO acknowledges with thanks the detailed recommenda- tions of H. Bleiholder and L.A. Hothorn for the revision of this Standard in 2006.
	3.4.4 Basic structure and sequence of analysis	References
	before explaining statution analysis of the wildowd. This vali- eries, the dias of each trial should be wildowd. This vali- teries and the explanation of the wildowd. This wildowd. Comply with the explanation procession of the analysis of the comply with the explanation procession. The explanation of the explanation of the explanation of the explanation of the disturbed by external or exceptional factors. They should be representative for the region and the year. The refer- ence products in all trials should perform normally. The infection pressure should be suitable (significant level for efficiency trials, weak level for selectively trials). The analysis of trial series is directed to pfficacy as well as to the treatmend-by-environment or treatment-by-factor interactions. The objective of the analysis of interactions is all environments and factors, and thus identify any situa- tions when efficacy rights the should and production wallable in FP 1/278 <i>Principle of yound and production and evolution</i> . This cannot be demonstrated appropriate to examine all interactions they may ensure the examine all interactions they may ensure of contrast- tion sciences of the situation of contrasts, in order to domonstrate the similarity of the treatment effects over all, or at least the majority of environments examine all interactions components by means of contrasts, contrast the monstrate the similarity of the treatment effects over all, or at least the majority of the treatment effects over all, or at least the majority of the treatment effects over all, or at least the majority of the treatment effects over all, or at least the majority of the treatment effects over all, or at least the majority of the treatment effects over all, or at least the majority of the treatment effects over all, or at least the majority of the treatment effects over all, or at least the majority of the treatment effects over all the only to be reatment by environment.	<ul> <li>A. (1995). Anapping of Dahan Calegorian Data. Weij, New York, A. (1996). Anapping of Dahan Calegorian Data. Weij, Baner F. Bohtmi, J. Marew W. &amp; Holson L. (1996). Testing strongings in mild-size experiments including active control. Statistics in Medicine (7): 2333–2364.</li> <li>B.R. (1980). Relating for Theoma, Davidythong and Auswertang von Verschen am Prilagen-Inhologiangstraffel, I. Virratelyologiang, J. Markow, M. (1995). Anapping and Auswertang von Verschen am Prilagen-Inhologiangstraffel. J. Nanoverlang data Excelorationalistic for Homan, Davidythong and Auswertang von Verschen mit Phenorphohandlampittek: J. Prinze, J. (1996).</li> <li>D. (1991). Relation data in statistic data data data essania de produktion han versch data data data data essania de produktion han versch data data data data essania de produktion han versch data data data data verschen data data data and the statistica data. J. Markov V. Roberta CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, ANPP (17): J. Prosent CEB (1996). La therase of Genein, A</li></ul>
	© 2012 OEPP/EPPO, Bulletin OEPP/EPPO Bulletin 42, 367-381	

pressures and, as a consequence provide important genotype discrimination, often produce high CVs.

Kempton R A, Fox P N (eds.) (1997). Statistical Methods for Plant Variety Evaluation. Chapman & Hall, London.

/// CV values from historical trials as a quality measure: a tool /// Peter Lancashire & Yinfei Li. Baver AG Crop Science /// 27 June 2019

The coefficient of variation (CV) is a **unitless** measure of **relative variability**. It is defined as the ratio of the standard deviation to the mean expressed as a percentage. (SAS 9.4 Help)

 $\widehat{c_V} = \frac{S}{\overline{x}}$ 

The coefficient of variation ... provides a good yard-stick for appreciating the precision possible in an

#### experiment, thereby aiding decisions on the sample size to be taken, and allowing **comparisons of** variability between experiments.

Ridgman W J (1975). Experimentation in Biology. An Introduction to Design and Analysis. Blackie, London.

The CV is sometimes used as a standard to gauge the **relative magnitude of error variation** compared with that from similar studies.

The CV on its own can be a poor indicator of quality. Trials that have been under disease, pest or other

Littell R C, Stroup W W, Freund R J (2002). SAS for Linear Models. SAS Institute, Cary NC.





## What is a typical coefficient of variation?



Depends on:

- // Site: intrinsic plot variability, application, accidents,
- // Assessment: yield, disease, pest, weed species, aggregation.
- // Method: measured, estimate, subjective rating, sample.
- // Values: low yield, early epidemic => higher CV.

Published values can be found for yield in some crops.

Not enough detail in most published reports.

Cannot compare with our assessments.

#### Solution: Use our own historical data.



#### BAYER E R

8

## Coefficient of variation and yield

CV can be country-dependent and related to yield.



nic solutions



9

### Coefficient of variation distribution



A histogram is more useful for validation.







The Scout system manages the whole process of planning, running, analysing, reporting and summarising field trials.

#### Scout field trials system



## Scout statistics for single trials calculates CV

Unique Col. ID Orig./Calc. Ray

male Sze da



Meets EPPO standard.

Automatic based on rules.

Rules ensure consistency.

Uses SAS PROC GLM.

Traditional transforms.

Saves statistics to database.

Includes coefficient of variation.

Used for registration reports.

Available for query and summary.



## CV ranges vary depend on crop/target and assessment type

agronomic solutions

Examples of reference distributions







Cout Tools - CVs

Crop

Target

TRZAW

SEPTTR

Crop

Disease



- // Works with a standard table template.
- // Recognises common field labels.
- // Finds assessment descriptions automatically.
- // Can enter own field labels or assessment descriptions.

Buttons step over sheets and assessments.

Compares CV with similar assessments.

- // Detailed: Histogram with current CV marked.
  - // Statistics: 20th percentile, median, 80th percentile.
- // Overview: Format the Excel table with colour scales.

#### Live demonstration.

Use key criteria including crop, target, assess type, assess unit to group CV values



BAYER





### CV inspector dashboard

#### Allows direct database connection

×

#### Look up a TPT ID

fa19

trial 2	column	crop	target	assess_type	assess_unit	transfor		
FA19ARGOZIGM01	1	GLXMA	SEPTGL	PESINC	%	ANGLE	12.2	^
	3	GLXMA	SEPTGL	PESSEV	%	ANGLE	16.2	
	4	GLXMA	SEPTGL	ABBOTT	%	ANGLE	16.2	
	6	GLXMA	SEPTGL	PESSEV	%	ANGLE	14.5	
	7	GLXMA	SEPTGL	ABBOTT	%	ANGLE	14.5	
	8	GLXMA	SEPTGL	DEFOLI	%	ANGLE	3.4	
	12	GLXMA	SEPTGL	PESSEV	%	ANGLE	22.5	
	13	GLXMA	SEPTGL	ABBOTT	96	ANGLE	22.5	
	14	GLXMA	SEPTGL	PESSEV	%	ANGLE	16.6	
	15	GLXMA	SEPTGL	ABBOTT	%	ANGLE	16.6	
	16	GLXMA	SEPTGL	PESSEV	AUDPC	NONE	22.5	
	17	GLXMA	SEPTGL	PESSEV	SAUDPC	NONE	22.5	
	18	GLXMA	SEPTGL	ABBOTT	%	NONE	22.5	
FA19ARGOZISA01	2	GLXMA	SEPTGL	PESSEV	%	ANGLE	11.2	
	3	GLXMA	SEPTGL	ABBOTT	%	ANGLE	11.2	
	4	GLXMA	SEPTGL	PESSEV	%	ANGLE	11.4	
	5	GLXMA	SEPTGL	ABBOTT	%	ANGLE	11.4	
	6	GLXMA	SEPTGL	PESSEV	%	ANGLE	13.0	
	7	GLXMA	SEPTGL	ABBOTT	%	ANGLE	13.0	
	8	GLXMA	SEPTGL	DEFOLI	%	ANGLE	14.6	
	14	GLXMA	SEPTGL	PESSEV	AUDPC	NONE	16.0	
	15	GLXMA	SEPTGL	PESSEV	SAUDPC	NONE	16.0	
	16	GLXMA	SEPTGL	ABBOTT	%	NONE	16.0	
FA19ARGOZISM01	5	GLXMA	SEPTGL	PESSEV	%	ANGLE	10.1	
	6	GLXMA	SEPTGL	ABBOTT	%	ANGLE	10.1	
	8	GLXMA	SEPTGL	PESSEV	%	ANGLE	16.1	
	9	GLXMA	SEPTGL	ABBOTT	%	ANGLE	16.1	
	10	GLXMA	SEPTGL	DEFOLI	%	ANGLE	9.7	Y

Select your criteria for CV distribution

crop		target		assess_type		assess_unit		transformation	
glxma	×	septgl	×	(AII)	•	(AII)	•	(AII)	•

#### CV value distribution



The data is filtered on crop, target, assess\_type, assess\_unit and transformation. The crop filter keeps LYPES. The target filter keeps XANTSP. The assess\_type filter keeps 228 of 308 members. The assess\_unit filter keeps 84 of 80 members. The transformation filter keeps 7 of 7 members.

The view is filtered on trial, which keeps 235 of 109,359 members. CV value for each assessment is found in last column.



# CV values from historical trials as a quality measure: a tool

CV-Werte von historischen Versuchen als Qualitätsmesslatte für Bewertungen: ein Werkzeug

# Discussion

# Questions



## **Discussion and questions**



Notes from the meeting

- // Do we use all assessments?
  - // Yes, from trials in the last ten years.
- // How do we advise colleagues to use CV values? Are there fixed upper limits?
  - // We recommend using CV values with biological expertise. There are no fixed upper limits, but with yield we exclude unusually high values.
- // As there is a relationship between CV and mean, would it be possible also to include the mean?
  - // In principle yes. A graphic would be possible but units and sample basis would give problems.
- # A later discussion about the trend for higher yields to have lower CV postulated the possible applicability of Taylor's Power Law.



# Thank you!

Peter Lancashire Yinfei Li